FDA advisors' scrutiny of MDMA therapy is 'temporary setback,' says Harvard researcher

Some Boston-area researchers said the decision by advisors to the U.S. Food and Drug Administration reflected challenges facing regulators as psychedelic treatments enter mainstream psychiatry.